EUVIMEDOpdag EUVIMED
Crossref

Tapinarof as a Likely Contact Allergen: Evidence From Patch Testing of Allergic and Irritant Contact Dermatitis

Shigeruko Iijima iD, Kayo Murayama, Noriko Takayama, Kayoko Matsunaga iD

Contact Dermatitis · 2026-05-25

DOI: 10.1111/cod.70191 ↗

At a glance

Journal article in Contact Dermatitis, published online on 2026-05-25. Written by Shigeruko Iijima and 3 co-authors. Institution: Division of Dermatology, Hanamizuki Clinic, Ibaraki, Japan. Cited 1 times so far (Crossref); 14 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Tapinarof cream 1% is a novel, non‐steroidal topical aryl hydrocarbon receptor‐modulating agent approved for the treatment of plaque psoriasis and atopic dermatitis (AD). There has only been one report of allergic sensitization to tapinarof cream.

Objectives

This study aimed to determine whether tapinarof cream‐induced contact dermatitis represents an allergic or irritant reaction, and to identify the causative allergen in allergic cases. Patients/Methods Nine patients (seven with psoriasis and two with AD) who developed contact dermatitis during treatment with tapinarof cream were included. Patch testing was performed with the cream as is ; tapinarof at concentrations of 1%, 0.3%, and 0.1% in petrolatum; and two additives (propylene glycol 10% aqueous solution and disodium edetate hydrate 1% in petrolatum).

Results

Patch testing with tapinarof cream as is was positive in four patients with psoriasis and both patients with AD. All six patients also showed dose–response relationships with tapinarof, increasing from 0.1% to 1%. The remaining three patients with psoriasis showed negative patch test results to both the cream as is and its individual components.

Conclusions

Tapinarof cream‐induced contact dermatitis may present as either an allergic or irritant reaction. In all six allergic cases, tapinarof was strongly suggested to be the causative allergen.

Subjects

Author keywords

active ingredientallergic contact dermatitisaryl hydrocarbon receptor‐modulating agentatopic dermatitisirritant contact dermatitispsoriasistapinarof (CAS RN 79338‐84‐4)tapinarof cream

Authors and institutions

  • Division of Dermatology, Hanamizuki Clinic, Ibaraki, Japan.
  • Department of Dermatology, Ryugasaki Saiseikai Hospital, Ibaraki, Japan.
  • General Incorporated Association SSCI-Net, Nagoya, Japan.
  • Fujita Health University, Toyoake, Japan.
  • Department of Dermatology and Allergy, Kariya Orthopedic Hospital, Kariya, Japan.

ORCID profiles: Shigeruko Iijima, Kayoko Matsunaga

Cite

APA

Iijima, S., Murayama, K., Takayama, N., & Matsunaga, K. (2026). Tapinarof as a Likely Contact Allergen: Evidence From Patch Testing of Allergic and Irritant Contact Dermatitis. Contact Dermatitis. https://doi.org/10.1111/cod.70191

Vancouver

Iijima S, Murayama K, Takayama N, Matsunaga K. Tapinarof as a Likely Contact Allergen: Evidence From Patch Testing of Allergic and Irritant Contact Dermatitis. Contact Dermatitis. 2026. doi:10.1111/cod.70191

BibTeX
@article{Iijima2026,
  author = {Iijima, Shigeruko and Murayama, Kayo and Takayama, Noriko and Matsunaga, Kayoko},
  title = {Tapinarof as a Likely Contact Allergen: Evidence From Patch Testing of Allergic and Irritant Contact Dermatitis},
  journal = {Contact Dermatitis},
  year = {2026},
  doi = {10.1111/cod.70191}
}
Start for free →